Uric Acid-Lowering Therapy with Febuxostat in Patients with Chronic Heart Failure and Hyperuricemia: A Prospective and Observational Cohort Study
High SUA levels are associated with increased all-cause mortality and rehospitalization for HF. Febuxostat-mediated SUA reduction significantly improved clinical outcomes in patients with HFpEF, particularly those with elevated SUA and BNP levels.
Authors
- Jiahan Ke (ORCID: https://orcid.org/0009-0007-1573-3169)
- Huasu Zeng (ORCID: https://orcid.org/0009-0006-2714-9229)
- Jun Gu (ORCID: https://orcid.org/0009-0007-4966-7630)
- Junfeng Zhang (ORCID: https://orcid.org/0000-0001-9530-3263)
- Changqian Wang (ORCID: https://orcid.org/0000-0002-5828-657X)
- Xiaohan Qiu (ORCID: https://orcid.org/0009-0005-3737-7981)
- Huafang Zhu (ORCID: https://orcid.org/0009-0008-8943-8178)
- Min Wang (ORCID: https://orcid.org/0000-0002-7712-6360)
Institutions
- Shanghai Ninth People's Hospital (CN)
- Shanghai Huangpu District Central Hospital (CN)
Publication Details
- Journal
- Balkan Medical Journal
- Published
- 2025-09-22
- DOI
- https://doi.org/10.4274/balkanmedj.galenos.2025.2025-6-168
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Shanghai Jiao Tong University